Item 8.01. Other Events.

As previously disclosed by InVivo Therapeutics Holdings Corp. (the "Company") on that certain Current Report on Form 8-K filed on December 8, 2020 with the U.S. Securities and Exchange Commission (the "SEC"), on December 4, 2020, the Company received a written notice (the "Initial Notice") from the Listing Qualifications department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share of the Company's common stock (the "Minimum Bid Price Requirement"). The Initial Notice provided the Company 180 calendar days, or until June 2, 2021, to regain compliance with the Minimum Bid Price Requirement.

On February 1, 2021, the Company received a letter (the "Compliance Letter") from the Listing Qualifications department of Nasdaq notifying the Company that it has regained compliance with the Minimum Bid Price Requirement. The Compliance Letter noted that (i) the Company's common stock had a closing bid price of at least $1.00 for a minimum of ten consecutive trading days from January 15, 2021 through January 29, 2021, and (ii) the Company has regained compliance with the Minimum Bid Price Requirement. Accordingly, Nasdaq considers the matter closed.

© Edgar Online, source Glimpses